在肝脏中对PCSK9进行表观遗传编辑，旨在诱导DNA甲基化和沉默基因表达，在表达人类PCSK9基因的转基因小鼠和食蟹猴中实现了LDL胆固醇水平的长期降低。 靶向人类 PCSK9 的强效表观遗传编辑器：降低低密度脂蛋白胆固醇水平的新突破 近日，来自 Chroma Medicine 的 ...

AstraZeneca has bought rights to an orally-active drug that inhibits PCSK9, offering a patient-friendly alternative to current cholesterol-lowering therapies that have to be delivered via a needle.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that binds to the LDL receptor on hepatocytes, promoting its internalization and degradation within the cell. [Repatha package ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

Some benefits of using Leqvio include: Some side effects of Leqvio include: Repatha is a monoclonal antibody targeting PCSK9 to reduce LDL-C. It is one of two medications in the PCSK9 inhibitor ...

of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for ...